About Biomaxima
Biomaxima is a company based in Lublin (Poland) founded in 2002. Biomaxima has raised $111.31 thousand across 2 funding rounds. The company has 126 employees as of December 31, 2024. Biomaxima offers products and services including Microbiology Products, Molecular Biology Kits, Laboratory Diagnostics, and Disposable Materials. Biomaxima operates in a competitive market with competitors including Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.
- Headquarter Lublin, Poland
- Employees 126 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biomaxima Sa
-
Annual Revenue
$12.84 M (USD)12.96as on Dec 31, 2024
-
Net Profit
$130.02 K (USD)-8.7as on Dec 31, 2024
-
EBITDA
$921.04 K (USD)105.03as on Dec 31, 2024
-
Total Equity Funding
$111.31 K (USD)
in 2 rounds
-
Latest Funding Round
$150.02 K (USD), Grant
Nov 07, 2016
-
Investors
Not available
-
Employee Count
126
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biomaxima
Biomaxima is a publicly listed company on the GPW with ticker symbol BMX in Poland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biomaxima
Biomaxima offers a comprehensive portfolio of products and services, including Microbiology Products, Molecular Biology Kits, Laboratory Diagnostics, and Disposable Materials.
Tools for microbial testing in clinical and research labs
Kits for cell cultures and molecular analysis in laboratories
Products for disease detection and lab diagnostics
Single-use items for safe laboratory procedures
Funding Insights of Biomaxima
Biomaxima has successfully raised a total of $111.31K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $150.02 thousand completed in November 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Biomaxima
Investment portfolio details for Biomaxima
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biomaxima
Detailed financials for Biomaxima
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biomaxima Comparisons
Peer comparison for Biomaxima
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biomaxima
Biomaxima operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Proteins, antibodies, and molecular tools are manufactured for research applications.
|
|
| Locked | Locked | Locked |
Research services, reagents, and kits for biotech applications are provided.
|
|
| Locked | Locked | Locked |
Molecular diagnostic device and kits
|
|
| Locked | Locked | Locked |
Molecular biology reagents and kits are supplied for research applications.
|
Detailed competitors of Biomaxima
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biomaxima
Complete news archive for Biomaxima
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biomaxima
Biomaxima was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Biomaxima is headquartered in Lublin, Poland. It is registered at Lublin, Lublin Voivodeship, Poland.
Biomaxima is a funded company, having raised a total of $111.31K across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Biomaxima is 126.
Annual revenue of Biomaxima is $12.84M as on Dec 31, 2024.
Biomaxima is engaged in the manufacturing and marketing of reagents for in vitro diagnostics.The companys product portfolio includes diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion selective analyzers and reagents, reagents and immunological analyzers of cardiac markers, glucometers for professional use, analysers for gasometric tests and critical blood parameters tests. It distributes its products in Poland and also exports to the markets of Lithuania, Latvia, Romania and France.
Biomaxima's top competitors include Abcam, Meridian Bioscience and Stem Cell Technologies.
Biomaxima offers Microbiology Products, Molecular Biology Kits, Laboratory Diagnostics, and Disposable Materials.
Yes, Biomaxima is publicly traded on GPW under the ticker symbol BMX.
The ticker symbol of Biomaxima is BMX on GPW.